A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
Launched by NOVO NORDISK A/S · Sep 27, 2018
Trial Information
Current as of October 08, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female, age greater than or equal to 18 years at the time of signing informed consent
- • Diagnosed with type 2 diabetes greater than or equal to 180 days prior to the day of screening
- • Treated with basal insulin once daily or twice daily for greater than or equal to 90 days prior to the day of screening
- • Stable daily dose for 90 days prior to the day of screening of the following anti-diabetic drugs or combination regimens: Any metformin formulations (greater than or equal to 1500 mg to less than or equal to 3000 mg or maximum tolerated or effective dose documented in subject's medical record), alone or in combination (including fixed-dose drug combination) with up to one additional of the following oral antidiabetic drugs: sulfonylureas, meglitinides, dipeptidyl peptidase-4 inhibitors or alpha-glucosidase inhibitors
- • Glycated haemoglobin (HbA1c) of greater than 7.5% to less than or less than or equal to 10.0% (greater than 58 mmol/mol to less than or equal to 86 mmol/mol)
- Exclusion Criteria:
- • History or presence of pancreatitis (acute or chronic)
- • Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening
- • Subjects presently classified as being in New York Heart Association Class IV
- • Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
- • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term bolus insulin treatment for a maximum of 14 days prior to the day of screening is allowed
- • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or an equally qualified health care provider (for example, optometrist) within the past 90 days prior to run-in
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bad Kreuznach, Germany
Friedrichsthal, Germany
Rehlingen Siersburg, Germany
New Dehli, New Delhi, India
Bratislava, Slovakia
Presov, Slovakia
Madrid, Spain
Münster, Germany
Córdoba, Spain
Pohlheim, Germany
Lublin, Poland
Zabrze, Poland
Galati, Romania
Plovdiv, Bulgaria
Zagreb, Croatia
Porto, Portugal
Bad Mergentheim, Germany
Schwabenheim, Germany
Rijeka, Croatia
Varna, Bulgaria
Osijek, Croatia
Athens, Greece
Chandigarh, Punjab, India
Ankara, Turkey
Gyula, Hungary
Zalaegerszeg, Hungary
Mumbai, Maharashtra, India
Cluj Napoca, Cluj, Romania
Durban, Kwazulu Natal, South Africa
Hohenmölsen, Germany
Wroclaw, Poland
Palma De Mallorca, Spain
Szeged, Hungary
Siedlce, Poland
Indore, Madhya Pradesh, India
Lubochna, Slovakia
Erzurum, Turkey
Adana, Turkey
Schweinfurt, Germany
Pulawy, Poland
Falkensee, Germany
Koper, Slovenia
Hamburg, Germany
Jaipur, Rajasthan, India
Madurai, Tamil Nadu, India
Kolkata, West Bengal, India
Johannesburg, Gauteng, South Africa
Antalya, Turkey
Karlovac, Croatia
Pécs, Hungary
Belgrade, Serbia
Nis, Serbia
Novi Sad, Serbia
Eisenach, Germany
Esslingen, Germany
Dimitrovgrad, Bulgaria
Ruse, Bulgaria
Stara Zagora, Bulgaria
Kragujevac, Serbia
Antequera, Spain
Sevilla, Spain
Bangalore, Karnataka, India
Málaga, Spain
Denizli, Turkey
Burgas, Bulgaria
Brezice, Slovenia
Saint Ingbert Oberwürzbach, Germany
Villingen Schwenningen, Germany
Ruda Slaska, Poland
Targu Mures, Mures, Romania
Lenasia, Gauteng, South Africa
Izmir, Turkey
Bialystok, Poland
Umkomaas, Kwazulu Natal, South Africa
Varazdin, Croatia
Skopje, North Macedonia
Alexandroupolis, Greece
Thessaloniki, Greece
Nagpur, Maharashtra, India
New Delhi, India
Coimbra, Portugal
Lisboa, Portugal
Hyderabad, Andhra Pradesh, India
Ludhiana, Punjab, India
Hyderbad, Telengana, India
Braga, Portugal
Delhi, New Delhi, India
Brno, Czechia
Pune, Maharashtra, India
Zajecar, Serbia
Piraeus, Greece
Essen, Germany
Almada, Portugal
Salgótarján, Hungary
Benoni, Gauteng, South Africa
Istanbul, Turkey
Larissa, Greece
Bardejov, Slovakia
Dolny Kubin, Slovakia
Levice, Slovakia
Prievidza, Slovakia
Bhubaneswar, Orissa, India
Mohali, Punjab, India
Poznan, Poland
Ogre, Latvia
Riga, Latvia
Kaunas, Lithuania
Segovia, Spain
Ahmedabad, Gujarat, India
Jerichow, Germany
Pretoria, Gauteng, South Africa
Sabinov, Slovakia
Olomouc, Czechia
Prostejov, Czechia
Fuenlabrada Madrid, Spain
Nachod, Czechia
Plzeň, Czechia
Cosmo City, Gauteng, South Africa
Trabzon, Turkey
Panevezys, Lithuania
Vilnius, Lithuania
Brasov, Romania
Oldenburg I. Holst, Germany
Murska Sobota, Slovenia
Pula, Croatia
Nagykanizsa, Hungary
Mlada Boleslav, Czechia
Targoviste, Dambovita, Romania
Ploiesti, Prahova, Romania
Pärnu, Estonia
Tallinn, Estonia
Viljandi, Estonia
Warsaw, Poland
Budapest, Hungary
Jesenice, Slovenia
Skorzewo, Poland
Almeria, Spain
Banja Luka, Bosnia And Herzegovina
Sarajevo, Bosnia And Herzegovina
Tuzla, Bosnia And Herzegovina
Byala, Bulgaria
Sofia, Bulgaria
Beroun, Czechia
Kladno Krocehlavy, Czechia
Berlin, Germany
Kiel Kronshagen, Germany
Leipzig, Germany
Stuhr, Germany
Stuttgart, Germany
Jelgava, Latvia
Sigulda, Latvia
Talsi, Latvia
Gorzow Wielkopolski, Poland
Lodz, Poland
Wierzchoslawice, Poland
Loures, Portugal
Setubal, Portugal
Martin, Slovakia
Nova Gorica, Slovenia
Patients applied
Trial Officials
Clinical Reporting Anchor and Disclosure (1452)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials